What type of study is this?

This is a Literature Review study.

September 27, 2025Journal of Clinical MedicineOpen Access

Immunosuppressive Therapies in Pulmonary Sarcoidosis: A Practical, Evidence-Based Review

View Full Paper

Ask AI

Bookmark

Authors

ZDZehra DhananiUniversity of California, San Diego RGRohit GuptaMilton Keynes Hospital

Discussion

Member takes

Implication

This review explores immunosuppressive therapies for pulmonary sarcoidosis, highlighting glucocorticoids and antimetabolites. Management needs to consider complications like pulmonary hypertension.

Key Points

Immunosuppressive therapies are crucial for managing pulmonary sarcoidosis effectively, especially in progressive cases.
Glucocorticoids are commonly used first-line, with doses generally starting at 20 to 40 mg/day, tapering based on response.
Second-line therapies such as methotrexate and anti-TNF agents may be necessary to control refractory disease.
An individualized approach is essential due to the heterogeneity of sarcoidosis and potential treatment-related harm.

Cite This Study

Dhanani et al. (2025) studied this question.

synapsesocial.com/papers/68d7cc6aeebfec0fc5238b9c https://doi.org/10.3390/jcm14196828

View Full Paper

Ask AI

Bookmark

Implication

This review explores immunosuppressive therapies for pulmonary sarcoidosis, highlighting glucocorticoids and antimetabolites. Management needs to consider complications like pulmonary hypertension.

Immunosuppressive Therapies in Pulmonary Sarcoidosis: A Practical, Evidence-Based Review

Discussion

Member takes

Implication

Key Points

Cite This Study

Immunosuppressive Therapies in Pulmonary Sarcoidosis: A Practical, Evidence-Based Review

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider